Diagnostic Utility of PAX8 and PAX2 Immunohistochemistry in the Identification of Metastatic Mullerian Carcinoma in Effusions

被引:32
作者
Wiseman, William [1 ]
Michael, Claire W. [1 ]
Roh, Michael H. [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
PAX8; PAX2; Mullerian; carcinoma; effusion; RENAL-CELL CARCINOMA; OVARIAN-CANCER; EXPRESSION; ADENOCARCINOMA; MARKER; BREAST; CYTOLOGY; GRADE; WT1; P53;
D O I
10.1002/dc.21442
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Morphologic distinction of Mullerian carcinomas from non-Mullerian carcinomas in effusion specimens by cytomorphology alone can be diagnostically challenging. Therefore, immunohistochemical adjuncts can be useful in differentiating Mullerian from non-Mullerian metastases. In this study, we evaluated the expression of PAX8 and PAX2 in malignant effusions collected from patients with known Mullerian and non-Mullerian carcinomas. Sections from cell blocks prepared from 152 effusion specimens (54 and 98 cases representing metastases from Mullerian and non-Mullerian primaries, respectively) were immunostained with rabbit polyclonal antibodies against PAX8 and PAX2. Immunopositivity was defined as the presence of strong nuclear staining in at least 25% of the tumor cells. Fifty-two (96%) and 13 (24%) of the 54 Mullerian carcinomas were positive for PAX8 and PAX2, respectively. PAX8 positivity was seen in only four (4%) of 98 non-Mullerian carcinomas; these represented metastasis from a large cell neuroendocrine lung carcinoma, papillary thyroid carcinoma, renal cell carcinoma, and acinic cell carcinoma of the parotid gland. PAX2 positivity was not seen in any of the non-Mullerian carcinomas. The results demonstrate that both PAX8 and PAX2 are highly specific markers for metastatic Mullerian carcinomas in cell block preparations from effusion specimens (96% and 100%, respectively). PAX8, however, is more sensitive than PAX2 in identifying Mullerian carcinomas in fluids (96% versus 24%). Overall, immunohistochemistry for PAX8 and PAX2 represent diagnostically useful adjuncts in identifying a Mullerian carcinoma as a source of a malignant effusion. Diagn. Cytopathol. 2011; 39: 651-656. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:651 / 656
页数:6
相关论文
共 27 条
  • [1] Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: Response to cisplatin-based chemotherapy
    Bar, JK
    Harlozinska, A
    Popiela, A
    Noga, L
    [J]. TUMOR BIOLOGY, 2001, 22 (02) : 83 - 91
  • [2] BEDROSSIAN CWM, 1994, MALIGNANT EFFUSIONS, pR11
  • [3] BILICI A, 2009, ARCH GYNECOL OBSTET
  • [4] Emerging roles for PAX8 in ovarian cancer and endosalpingeal development
    Bowen, Nathan J.
    Logani, Sanjay
    Dickerson, Erin B.
    Kapa, Laura B.
    Akhtar, Mariam
    Benigno, Benedict B.
    McDonald, John F.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 331 - 337
  • [5] Brown RW, 1997, AM J CLIN PATHOL, V107, P12
  • [6] Cangi M G, 2000, Adv Clin Path, V4, P183
  • [7] Chang MC, 2008, CANCER CYTOPATHOL, V114, P353
  • [8] PAX 2: A Novel Mullerian Marker for Serous Papillary Carcinomas to Differentiate From Micropapillary Breast Carcinoma
    Chivukula, Mamatha
    Dabbs, David J.
    O'Connor, Siobhan
    Bhargava, Rohit
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2009, 28 (06) : 570 - 578
  • [9] DAVIDSON B, 2010, J CELL MOL MED
  • [10] The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics - An immunohistochemical study with comparison to renal cell carcinoma marker
    Gokden, Neriman
    Gokden, Murat
    Phan, Dan C.
    MeKenney, Jesse K.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (10) : 1462 - 1467